| HALÁMKOVÁ, Jana, Igor KISS, Zdeněk PAVLOVSKÝ, Jiří TOMÁŠEK, Jiří JARKOVSKÝ, Zbyněk ČECH, D. BEDNAROVA, Štěpán TUČEK, L. HANAKOVA, Mojmír MOULIS, Jiřina ZAVŘELOVÁ, M. MAN, Petr BENDA, Oldřich ROBEK, Zdeněk KALA and Miroslav PENKA. Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients. Neoplasma. BRATISLAVA: SLOVAK ACAD SCIENCES, 2013, vol. 60, No 2, p. 151-159. ISSN 0028-2685. Available from: https://dx.doi.org/10.4149/neo_2013_020. |
Other formats:
BibTeX
LaTeX
RIS
@article{1161702,
author = {Halámková, Jana and Kiss, Igor and Pavlovský, Zdeněk and Tomášek, Jiří and Jarkovský, Jiří and Čech, Zbyněk and Bednarova, D. and Tuček, Štěpán and Hanakova, L. and Moulis, Mojmír and Zavřelová, Jiřina and Man, M. and Benda, Petr and Robek, Oldřich and Kala, Zdeněk and Penka, Miroslav},
article_location = {BRATISLAVA},
article_number = {2},
doi = {http://dx.doi.org/10.4149/neo_2013_020},
keywords = {plasminogen activator system; gastrointestinal cancer; plasminogen activator inhibitor 1; -675 4G/5G gene polymorphism},
language = {eng},
issn = {0028-2685},
journal = {Neoplasma},
title = {Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients},
volume = {60},
year = {2013}
}
TY - JOUR
ID - 1161702
AU - Halámková, Jana - Kiss, Igor - Pavlovský, Zdeněk - Tomášek, Jiří - Jarkovský, Jiří - Čech, Zbyněk - Bednarova, D. - Tuček, Štěpán - Hanakova, L. - Moulis, Mojmír - Zavřelová, Jiřina - Man, M. - Benda, Petr - Robek, Oldřich - Kala, Zdeněk - Penka, Miroslav
PY - 2013
TI - Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients
JF - Neoplasma
VL - 60
IS - 2
SP - 151-159
EP - 151-159
PB - SLOVAK ACAD SCIENCES
SN - 00282685
KW - plasminogen activator system
KW - gastrointestinal cancer
KW - plasminogen activator inhibitor 1
KW - -675 4G/5G gene polymorphism
N2 - Plasminogen activator ihnibitor (PAI 1) belongs to the plasminogen activator system, which is part of the metastatic cascade and significantly contributes to invasive growth and angiogenesis of malignant tumors. Its plasma level is normally low but 4G/4G homozygotes have higher concentrations of PAI 1. This genotype may be associated with worse prognosis and proximal location of colorectal cancer than 5G/5G homozygotes. In our prospective evaluation we examined plasma level PAI 1 (using photometric microplate method ELISA) pre-surgery and, subsequently, 6-8 weeks later, from 80 patients. For the PAI 1 rs1799889 -675 4G/5G polymorphism test the PCR amplification was used. Analysis of collected data was confirmed that significantly higher plasma levels of PAI 1 were found in patients before starting therapy, which decreased (p=0.004) after initiation of treatment. Patients with higher plasma level PAI 1 before (p=0.013) and after therapy (p=0.004) had significantly shorter survival. We found no relationship between polymorphisms of PAI 1 (-675 4G/5G) in relation to stage, survival or tumor location. PAI 1 is useful as a negative marker of prognosis and could be advantageous when planning adjuvant treatment of patients with colorectal carcinoma. Although opinions on the importance of polymorphisms of PAI 1 in relation to the prognosis are not uniform, it does seem that their role in the prognosis of patients with colorectal cancer is not essential.
ER -
HALÁMKOVÁ, Jana, Igor KISS, Zdeněk PAVLOVSKÝ, Jiří TOMÁŠEK, Jiří JARKOVSKÝ, Zbyněk ČECH, D. BEDNAROVA, Štěpán TUČEK, L. HANAKOVA, Mojmír MOULIS, Jiřina ZAVŘELOVÁ, M. MAN, Petr BENDA, Oldřich ROBEK, Zdeněk KALA and Miroslav PENKA. Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients. \textit{Neoplasma}. BRATISLAVA: SLOVAK ACAD SCIENCES, 2013, vol.~60, No~2, p.~151-159. ISSN~0028-2685. Available from: https://dx.doi.org/10.4149/neo\_{}2013\_{}020.
|
